Article

FDA Clearance Given to Phase 3 Clinical Trial of Nolasiban for Women Undergoing Embryo Transfer

Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the U.S. pivotal Phase 3 clinical trial in nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).

Officials from the FDA have allowed ObsEva to begin enrolling patients in IMPLANT 3, the United States' Phase 3 clinical trial in nolasiban for women undergoing embryo transfer following in-vitro fertilization (IVF).

Nolasiban, an oral oxytocin receptor antagonist, is currently being studied in a confirmatory Phase 3 European trial known as IMPLANT 4. IMPLANT 3 will be the first study of nolasiban in the United States and will evaluate efficacy for an increasing the number of live births and safety, compared to placebo.

Assisted Reproductive Technology treatments are performed on more than 2 million reproductive-age couples each year. Nolasiban’s success could help reduce uterine contractions and suboptimal blood flow to the uterus at the time of embryo transfer.

REFERENCE

ObsEva announces clearance to initiate pivotal US phase 3 clinical trial (IMPLANT 3) of nolasiban in women undergoing embryo transfer following IVF [news release]. Geneva, Switzerland and Boston, MA; October 31, 2019: ObsEva Press Releases. https://www.obseva.com/pressrelease-detail-2/?pr=2665. Accessed October 31, 2019.

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards